Dr. Geert Mudde
Geert C. Mudde received a Ph.D. in immunology from the University of Utrecht in 1985 and started his international professional career at the Swiss Institute for Asthma and Allergy Research
in Davos in 1989. In 1992 he joined the pharmaceutical/biotech industry, where he held several senior management positions such as “Deputy Head of the Immunology Department” at the
Novartis Research Institute in Vienna, Austria, “Director of Allergy and Inflammation/Immunology” at the Parke Davis Research Institute in Fresnes, France, “Director Immunology” at
Ingenium Pharmaceuticals, Martinsried, Germany, and “VP Exploratory Research” at igeneon AG, Vienna, Austria. Finally, in 2006, while joining Baxter BioScience in Vienna as interim
“Director Discovery Research”, Dr. Mudde co-founded the biotech company f-star GmbH, where he served as “Chief Scientific Officer” until 2009, when he started to prepare for the
foundation of S-TARget therapeutics.
Since 2010 he serves as CSO of S-TARget therapeutics. In 2013 he co-founded
ML and TYG Oncology Ltd.
REDL Life Science Patent Attorneys